Evidence map›Paper›PMID 25487190›Full record

ReviewMetabolism: clinical and experimental2015

Biomarkers of cardiovascular disease risk in women.

JoAnn E Manson, Shari S Bassuk

Open access · greenAbstract readReview
In one paragraph

Review in Metabolism: clinical and experimental, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.Journal of the American College of Cardiology · 2019
    Observational
  10. Review
  11. Sex Differences in Outcomes after Stroke in Patients with Diabetes in Ontario, Canada.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

JoAnn E MansonDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, 3rd FL, Boston, Massachusetts 02215. Electronic address: jmanson@partners.org.
Shari S BassukDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue East, 3rd FL, Boston, Massachusetts 02215.
Brigham and Women's Hospital · USHarvard University · US

Funding

RISK FACTORS FOR CVD IN WOMENR01HL034594 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI JoAnn Elisabeth Manson, Lu Qi · 1985 to 2026
$13.8M
NHLBI NIH HHS R01 HL034594
6 · The paper itself

Abstract

Cardiovascular disease (CVD), including coronary heart disease and stroke, is the leading cause of death among U.S. women and men. Established cardiovascular risk factors such as smoking, diabetes, hypertension, and elevated total cholesterol, and risk prediction models based on such factors, perform well but do not perfectly predict future risk of CVD. Thus, there has been much recent interest among cardiovascular researchers in identifying novel biomarkers to aid in risk prediction. Such markers include alternative lipids, B-type natriuretic peptides, high-sensitivity troponin, coronary artery calcium, and genetic markers. This article reviews the role of traditional cardiovascular risk factors, risk prediction tools, and selected novel biomarkers and other exposures in predicting risk of developing CVD in women. The predictive role of novel cardiovascular biomarkers for women in primary prevention settings requires additional study, as does the diagnostic and prognostic utility of cardiac troponins for acute coronary syndromes in clinical settings. Sex differences in the clinical expression and physiology of metabolic syndrome may have implications for cardiovascular outcomes. Consideration of exposures that are unique to, or more prevalent in, women may also help to refine cardiovascular risk estimates in this group.

Indexed as

Apolipoprotein A-IApolipoproteins BBiomarkersBody Fat DistributionCalciumCardiovascular DiseasesFemaleHumansLipoprotein(a)MaleMetabolic SyndromeNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsPrimary PreventionRisk AssessmentAPOA1 protein, humanApolipoprotein A-IApolipoproteins BBiomarkersCalciumLipoprotein(a)Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin TBiomarkersCardiovascular diseaseCoronary risk factorsRisk predictionWomen

Identifiers

PMID25487190
PMCPMC4310209
OpenAlexW2031868697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.